CNSide at SNO 2024 – CSF Assay

Plus Therapeutics to Present Groundbreaking Data on CNSide™ Cerebrospinal Fluid Assay at SNO Annual Meeting in Houston

Plus Therapeutics is excited to present new findings at the Society for Neuro-Oncology (SNO) Annual Meeting in Houston, focusing on our CNSide™ Cerebrospinal Fluid (CSF) Assay and its potential for advancing the treatment of leptomeningeal metastases (LM).

Key Highlights of the Presentation:

• CNSide CSF Assay Analysis: The CNSide™ assay analyzed a total of 258 CSF samples from 66 LM patients across five leading institutions.
• Actionable Mutational Changes: The data revealed extensive, actionable mutational changes that could provide critical insights into personalized treatment options for leptomeningeal metastasis patients.
• Longitudinal Biomarkers: The CNSide assay also identified clinically relevant longitudinal biomarkers that may help in monitoring disease progression and treatment response.

Why This is Important for Leptomeningeal Metastases Patients

Leptomeningeal metastasis (LM), which occurs when cancer spreads to the membranes surrounding the brain and spinal cord, is a challenging complication for patients with metastatic cancer. The ability to detect mutational changes and identify biomarkers through cerebrospinal fluid analysis has the potential to revolutionize the way clinicians diagnose and treat this life-threatening condition.

Learn More About the CNSide™ Assay and Our SNO Presentation:

For full details on this exciting presentation and the latest advancements in LM treatment and cerebrospinal fluid analysis, visit our press release here: Plus Therapeutics Press Releases

Don’t Miss Out

Be sure to join us at SNO 2024 for in-depth discussions on the latest oncology research, clinical trials, and innovative therapies for metastatic cancer, especially in the area of brain metastasis and leptomeningeal disease.

#LeptomeningealMetastasis #CNSideAssay #CerebrospinalFluid #BrainCancer #MetastaticCancer #OncologyResearch #ClinicalTrials #CancerTherapeutics #SNOAnnualMeeting #CancerBiomarkers #BrainMetastasis #Biomarkers #PatientCare #CancerDiagnostics #PlusTherapeutics #SNO2024